Harrow Closes Acquisition of TYRVAYA®
Key Highlights
- ➤Harrow closed its worldwide TYRVAYA acquisition, excluding Japan, from Viatris
- ➤Harrow paid $30 million upfront and may owe $70 million in sales milestones
- ➤Harrow expects TYRVAYA to contribute more than $30 million revenue in 2027
- ➤Approximately 40 Viatris personnel are expected to join Harrow during Q4 2026
- ➤TYRVAYA adds a differentiated nasal spray to Harrow’s VEVYE dry-eye portfolio
Expert Statements
Mark L. Baum, Chief Executive Officer of Harrow
“Today marks an important step forward for Harrow and for the physicians and patients we serve,”
Mark L. Baum, Chief Executive Officer of Harrow
“Dry eye disease is complex and multifactorial, and there is no single treatment approach that works for every patient.”
Mark L. Baum, Chief Executive Officer of Harrow
“VEVYE and TYRVAYA approach dry eye differently and give eyecare professionals two distinct tools from one organization committed to serving this market.”
Mark L. Baum, Chief Executive Officer of Harrow
“VEVYE remains the cornerstone of our dry eye franchise, while TYRVAYA gives us an established, complementary prescription brand with a unique route of administration and an existing base of physicians who know and use the product.”
Mark L. Baum, Chief Executive Officer of Harrow
“We see a significant commercial opportunity ahead.”
Mark L. Baum, Chief Executive Officer of Harrow
“TYRVAYA comes to Harrow with meaningful physician awareness, an established prescription base, and years of real-world clinical experience.”
Mark L. Baum, Chief Executive Officer of Harrow
“By combining that foundation with Harrow’s expanding Ocular Surface commercial organization, market access capabilities, and focus on patient access and affordability, we believe we can introduce TYRVAYA to many more eyecare professionals and patients while also expanding awareness of VEVYE among existing TYRVAYA prescribers.”
Laura Periman, MD, Board-certified ophthalmologist at Periman Eye Institute
“TYRVAYA is a product I have used extensively in my dry eye practice, and its nasal route of administration makes it a truly differentiated treatment option.”
Laura Periman, MD, Board-certified ophthalmologist at Periman Eye Institute
“For patients who struggle with eye drops or contact lens wearers who want an option that does not require removing their lenses, TYRVAYA can fit very well into their treatment routine.”
Laura Periman, MD, Board-certified ophthalmologist at Periman Eye Institute
“I have seen firsthand the value of stimulating a patient’s own tear production, and I am pleased to see TYRVAYA become part of Harrow, a company deeply committed to eyecare and patient access.”
Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute
“VEVYE has become an important option in my dry eye practice because of the clinical benefits it can provide, and TYRVAYA is another therapy I know well and have prescribed for years.”
Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute
“The two products approach dry eye very differently: VEVYE is applied directly to the ocular surface, while TYRVAYA is administered nasally and stimulates natural tear production through a distinct mechanism.”
Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute
“Having therapies with different mechanisms and routes of administration gives me greater flexibility to individualize treatment based on each patient’s needs.”
Paul Karpecki, OD, Director of Cornea and External Disease at Kentucky Eye Institute
“I’m pleased to see both products together at Harrow, giving physicians more options for patients with this chronic disease.”
NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA(®) (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Viatris retained the rights to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to TYRVAYA’s net sales, for potential total consideration of up to $100 million. The closing payment was funded with cash on hand.
TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is the first and only FDA-approved nasal spray for DED. Unlike topical ophthalmic therapies, TYRVAYA is administered through the nose and is thought to activate the trigeminal parasympathetic pathway to stimulate basal tear production. TYRVAYA is approved in the U.S., China, and Taiwan, with marketing applications pending in additional markets.
Get started
Create a free account to read the full story.